The Chicago Entrepreneur

AstraZeneca to pay up to $2 billion to license cardiovascular drug

AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.

Previous post Tether to release documentary on its mission to bring financial freedom on 10th anniversary
Next post The strong jobs report leads Morgan Stanley to ditch a stock-market call it made just two weeks ago